Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

Hovione Buys Stake in Zhejiang Hisyn

publication date: Mar 3, 2008

Hovione, a Portuguese maker of active pharmaceutical ingredients, paid “in excess” of 13 million euros ($19.5 million) to buy 75% of the capital of Zhejiang Hisyn Pharmaceutical. Like Hovione, Zhejiang Hisyn is in the business of manufacturing active pharmaceutical ingredients. Hovione said the investment in Hisyn will lower its production costs while increasing production. With the lower costs, Hovione said it would be able to supply APIs to pharmas in China, India and Brazil. More details...



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China